Session Type
Date Time
Local Date Time

Six presentations by invited speakers will provide a more detailed overview of some of the approaches for targeting and engineering cells in vivo, including efforts to modify hematopoietic stem cells and T cells, or to directly excise proviral HIV genomes from cells in the rebound-competent reservoir.

1 min
Co-chairs introduction
Agnieszka CZECHOWICZ, Stanford University, United States
Daiquiri ROBINSON, Penn Center for AIDS Research, United States

15 min
HDAd vectors for targeting HSCs in vivo
Andre LIEBER, University of Washington, United States

15 min
Progress towards in vivo modification of HSCs by capsid-engineered AAV vectors
Hildegard BUENING, Hannover Medical School, Germany
15 min
In vivo targeting of hematopoietic cells with lentiviral vectors
Christian BUCHHOLZ, Paul-Ehlich-Institut, Germany
15 min
Excision of HIV proviral genomes in vivo
Joachim HAUBER, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Germany

15 min
LNPs targeting HSCs in vivo
Sean BURNS, Intellia Therapeutics, United States

14 min
In vivo targeted gene therapy for Sickle Cell Disease
Marta ORTEGA-VALLE, GreenLight Biosciences, United States